Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 327

1.

Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration.

Marshall RD, Collins A, Escolar ML, Jinnah HA, Klopstock T, Kruer MC, Videnovic A, Robichaux-Viehoever A, Burns C, Swett LL, Revicki DA, Bender RH, Lenderking WR.

Orphanet J Rare Dis. 2019 Jul 12;14(1):174. doi: 10.1186/s13023-019-1142-1.

2.

Retraction Note to: Content validity and psychometric evaluation of functional assessment of chronic illness therapy-fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA.

J Patient Rep Outcomes. 2019 May 28;3(1):32. doi: 10.1186/s41687-019-0125-2.

3.

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA.

J Patient Rep Outcomes. 2019 May 20;3(1):30. doi: 10.1186/s41687-019-0115-4.

4.

Can Methods Developed for Interpreting Group-level Patient-reported Outcome Data be Applied to Individual Patient Management?

King MT, Dueck AC, Revicki DA.

Med Care. 2019 May;57 Suppl 5 Suppl 1:S38-S45. doi: 10.1097/MLR.0000000000001111.

PMID:
30985595
5.

Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma.

Globe G, Wiklund I, Mattera M, Zhang H, Revicki DA.

J Patient Rep Outcomes. 2019 Apr 3;3(1):22. doi: 10.1186/s41687-019-0109-2.

6.

A Scale to Assess Activities of Daily Living in Pantothenate Kinase-Associated Neurodegeneration.

Marshall RD, Collins A, Escolar ML, Jinnah HA, Klopstock T, Kruer MC, Videnovic A, Robichaux-Viehoever A, Swett L, Revicki DA, Bender RH, Lenderking WR.

Mov Disord Clin Pract. 2019 Jan 22;6(2):139-149. doi: 10.1002/mdc3.12716. eCollection 2019 Feb.

PMID:
30838313
7.

The American neurogastroenterology and motility society gastroparesis cardinal symptom index-daily diary (ANMS GCSI-DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis.

Revicki DA, Speck RM, Lavoie S, Puelles J, Kuo B, Camilleri M, Almansa C, Parkman HP.

Neurogastroenterol Motil. 2019 Apr;31(4):e13553. doi: 10.1111/nmo.13553. Epub 2019 Feb 7.

PMID:
30734412
8.

Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings.

Galipeau N, Klooster B, Krohe M, Tang DH, Revicki DA, Cella D.

J Patient Rep Outcomes. 2019 Feb 7;3(1):10. doi: 10.1186/s41687-019-0098-1.

9.

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA.

J Patient Rep Outcomes. 2019 Jan 24;3(1):5. doi: 10.1186/s41687-019-0094-5. Corrected and republished in: J Patient Rep Outcomes. 2019 May 20;3(1):30. Retraction in: J Patient Rep Outcomes. 2019 May 28;3(1):32.

10.

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.

Mirkin S, Graham S, Revicki DA, Bender RH, Bernick B, Constantine GD.

Menopause. 2019 Jan 9;26(6):637-642. doi: 10.1097/GME.0000000000001294.

11.

The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis.

Revicki DA, Lavoie S, Speck RM, Puelles J, Kuo B, Camilleri M, Almansa C, Parkman HP.

J Patient Rep Outcomes. 2018 Dec 13;2(1):61. doi: 10.1186/s41687-018-0081-2.

12.

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.

Constantine GD, Revicki DA, Kagan R, Simon JA, Graham S, Bernick B, Mirkin S.

Menopause. 2019 May;26(5):513-519. doi: 10.1097/GME.0000000000001261.

13.

Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS®-Preference (PROPr) Scoring System.

Dewitt B, Feeny D, Fischhoff B, Cella D, Hays RD, Hess R, Pilkonis PA, Revicki DA, Roberts MS, Tsevat J, Yu L, Hanmer J.

Med Decis Making. 2018 Aug;38(6):683-698. doi: 10.1177/0272989X18776637. Epub 2018 Jun 26.

14.

Systematic literature review and assessment of patient-reported outcome instruments in sickle cell disease.

Sarri G, Bhor M, Abogunrin S, Farmer C, Nandal S, Halloway R, Revicki DA.

Health Qual Life Outcomes. 2018 May 21;16(1):99. doi: 10.1186/s12955-018-0930-y. Review.

15.

Linguistic and Cultural Validation of Patient-Reported Outcomes Used in Clinical Trials.

Althof SE, Rosen RC, Revicki DA.

J Sex Med. 2018 Feb;15(2):115-117. doi: 10.1016/j.jsxm.2017.11.017. No abstract available.

PMID:
29425661
16.

Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment.

Ng-Mak D, Poon JL, Roberts L, Kleinman L, Revicki DA, Rajagopalan K.

Patient Prefer Adherence. 2017 Dec 28;12:35-44. doi: 10.2147/PPA.S151561. eCollection 2018.

17.

Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.

Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B.

Value Health. 2017 Sep;20(8):1174-1179. doi: 10.1016/j.jval.2016.11.020. Epub 2017 Jun 16.

18.

Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary.

Kawata AK, Hsieh R, Bender R, Shaffer S, Revicki DA, Bayliss M, Buse DC, Desai P, Sapra S, Ortmeier B, Hareendran A.

Headache. 2017 Oct;57(9):1385-1398. doi: 10.1111/head.13162. Epub 2017 Aug 30.

PMID:
28857154
19.

Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire Short Form (HIS-Q-SF).

Gelhorn HL, Roberts LJ, Khandelwal N, Revicki DA, DeRogatis LR, Dobs A, Hepp Z, Miller MG.

J Sex Med. 2017 Aug;14(8):1046-1058. doi: 10.1016/j.jsxm.2017.05.013.

PMID:
28760247
20.

Development and validation of the self-reported PROMIS pediatric pain behavior item bank and short form scale.

Cunningham NR, Kashikar-Zuck S, Mara C, Goldschneider KR, Revicki DA, Dampier C, Sherry DD, Crosby L, Carle A, Cook KF, Morgan EM.

Pain. 2017 Jul;158(7):1323-1331. doi: 10.1097/j.pain.0000000000000914.

21.

The Dutch-Flemish PROMIS Physical Function item bank exhibited strong psychometric properties in patients with chronic pain.

Crins MHP, Terwee CB, Klausch T, Smits N, de Vet HCW, Westhovens R, Cella D, Cook KF, Revicki DA, van Leeuwen J, Boers M, Dekker J, Roorda LD.

J Clin Epidemiol. 2017 Jul;87:47-58. doi: 10.1016/j.jclinepi.2017.03.011. Epub 2017 Mar 28.

PMID:
28363734
22.

Does personality affect health-related quality of life? A systematic review.

Huang IC, Lee JL, Ketheeswaran P, Jones CM, Revicki DA, Wu AW.

PLoS One. 2017 Mar 29;12(3):e0173806. doi: 10.1371/journal.pone.0173806. eCollection 2017. Review.

23.

Evaluating the Measurement Properties of the Self-Assessment of Treatment Version II, Follow-Up Version, in Patients with Painful Diabetic Peripheral Neuropathy.

van Nooten F, Trundell D, Staniewska D, Chen J, Davies EW, Revicki DA.

Pain Res Treat. 2017;2017:6080648. doi: 10.1155/2017/6080648. Epub 2017 Jan 16.

24.

Standards for Clinical Trials in Male and Female Sexual Dysfunction: III. Unique Aspects of Clinical Trials in Male Sexual Dysfunction.

Fisher WA, Gruenwald I, Jannini EA, Lev-Sagie A, Lowenstein L, Pyke RE, Reisman Y, Revicki DA, Rubio-Aurioles E.

J Sex Med. 2017 Jan;14(1):3-18. doi: 10.1016/j.jsxm.2016.08.016.

PMID:
28065358
25.

Standards for Clinical Trials in Male and Female Sexual Dysfunction: IV. Unique Aspects of Clinical Trials in Female Sexual Dysfunction.

Fisher WA, Gruenwald I, Jannini EA, Lev-Sagie A, Lowenstein L, Pyke RE, Reisman Y, Revicki DA, Rubio-Aurioles E.

J Sex Med. 2017 Jan;14(1):19-26. doi: 10.1016/j.jsxm.2016.09.022.

PMID:
28065357
26.

Editorial Comment: "Quantifying Barriers to Improvement of Treatment Satisfaction in Men With Erectile Dysfunction: Use of Person-Item Maps".

Revicki DA.

J Sex Med. 2017 Jan;14(1):160-161. doi: 10.1016/j.jsxm.2016.11.313. No abstract available.

PMID:
28065348
27.

Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary.

Higgins PDR, Harding G, Revicki DA, Globe G, Patrick DL, Fitzgerald K, Viswanathan H, Donelson SM, Ortmeier BG, Chen WH, Leidy NK, DeBusk K.

J Patient Rep Outcomes. 2017;2(1):26. doi: 10.1186/s41687-018-0049-2. Epub 2018 May 30.

28.

Development and validation of the Crohn's disease patient-reported outcomes signs and symptoms (CD-PRO/SS) diary.

Higgins PDR, Harding G, Leidy NK, DeBusk K, Patrick DL, Viswanathan HN, Fitzgerald K, Donelson SM, Cyrille M, Ortmeier BG, Wilson H, Revicki DA, Globe G.

J Patient Rep Outcomes. 2017;2(1):24. doi: 10.1186/s41687-018-0044-7. Epub 2018 May 9.

29.

The content validity of the PSS in patients with plaque psoriasis.

Rentz AM, Skalicky AM, Burslem K, Becker K, Kaschinski D, Esser D, Revicki DA.

J Patient Rep Outcomes. 2017;1(1):4. doi: 10.1186/s41687-017-0004-7. Epub 2017 Sep 12.

30.

Standards for Clinical Trials in Male and Female Sexual Dysfunction: II. Patient-Reported Outcome Measures.

Fisher WA, Gruenwald I, Jannini EA, Lev-Sagie A, Lowenstein L, Pyke RE, Reisman Y, Revicki DA, Rubio-Aurioles E.

J Sex Med. 2016 Dec;13(12):1818-1827. doi: 10.1016/j.jsxm.2016.08.015.

PMID:
27914562
31.

Standards for Clinical Trials in Male and Female Sexual Dysfunction: I. Phase I to Phase IV Clinical Trial Design.

Fisher WA, Gruenwald I, Jannini EA, Lev-Sagie A, Lowenstein L, Pyke RE, Reisman Y, Revicki DA, Rubio-Aurioles E.

J Sex Med. 2016 Dec;13(12):1805-1817. doi: 10.1016/j.jsxm.2016.09.021.

PMID:
27914561
32.

Development of the Hypogonadism Impact of Symptoms Questionnaire Short Form: Qualitative Research.

Gelhorn HL, Bodhani AR, Wahala LS, Sexton C, Landrian A, Miller MG, Derogatis L, Dobs A, Revicki DA.

J Sex Med. 2016 Nov;13(11):1729-1736. doi: 10.1016/j.jsxm.2016.09.007. Epub 2016 Oct 4.

33.

Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire.

Gelhorn HL, Dashiell-Aje E, Miller MG, DeRogatis LR, Dobs A, Seftel AD, Althof SE, Brod M, Revicki DA.

J Sex Med. 2016 Nov;13(11):1737-1749. doi: 10.1016/j.jsxm.2016.09.006. Epub 2016 Sep 28.

34.

A PROMIS Measure of Neuropathic Pain Quality.

Askew RL, Cook KF, Keefe FJ, Nowinski CJ, Cella D, Revicki DA, Morgan DeWitt EM, Michaud K, Trence DL, Amtmann D.

Value Health. 2016 Jul-Aug;19(5):623-30. doi: 10.1016/j.jval.2016.02.009. Epub 2016 Apr 6.

35.

Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3.

Hays RD, Revicki DA, Feeny D, Fayers P, Spritzer KL, Cella D.

Pharmacoeconomics. 2016 Oct;34(10):1015-22. doi: 10.1007/s40273-016-0408-x.

36.

Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behavior.

Askew RL, Cook KF, Revicki DA, Cella D, Amtmann D.

J Clin Epidemiol. 2016 May;73:103-11. doi: 10.1016/j.jclinepi.2015.08.035. Epub 2016 Feb 27.

37.

Introduction to special section on patient-reported outcomes in nonstandard settings.

Schwartz CE, Revicki DA.

Qual Life Res. 2016 Mar;25(3):493-5. doi: 10.1007/s11136-016-1228-3. Epub 2016 Jan 23. No abstract available.

PMID:
26803828
38.

Content validity of the Sheehan Irritability Scale in patients with major depressive disorder.

Mannix S, Hassan M, Tummala R, Locklear JC, Revicki DA, Khan S, Dunbar GC, Eriksson H, Sheehan DV.

Int Clin Psychopharmacol. 2016 Mar;31(2):110-7. doi: 10.1097/YIC.0000000000000113.

PMID:
26655731
39.

Adolescent body weight and health-related quality of life rated by adolescents and parents: the issue of measurement bias.

Gandhi PK, Revicki DA, Huang IC.

BMC Public Health. 2015 Nov 30;15:1192. doi: 10.1186/s12889-015-2533-4.

40.

Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder.

Khan SA, Revicki DA, Hassan M, Locklear JC, Friedman LA, Mannix S, Tummala R, Dunbar GC, Eriksson H, Sheehan DV.

J Clin Psychiatry. 2016 Aug;77(8):1080-6. doi: 10.4088/JCP.14m09719.

PMID:
26579723
41.

Content Validity of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q): A Patient-Reported Outcome Measure to Evaluate Symptoms of Hypogonadism.

Gelhorn HL, Vernon MK, Stewart KD, Miller MG, Brod M, Althof SE, DeRogatis LR, Dobs A, Seftel AD, Revicki DA.

Patient. 2016 Apr;9(2):181-90. doi: 10.1007/s40271-015-0138-8.

PMID:
26334870
42.

The PROMIS of QALYs.

Hanmer J, Feeny D, Fischhoff B, Hays RD, Hess R, Pilkonis PA, Revicki DA, Roberts MS, Tsevat J, Yu L.

Health Qual Life Outcomes. 2015 Aug 11;13:122. doi: 10.1186/s12955-015-0321-6.

43.

Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis.

Wilson HD, Mutebi A, Revicki DA, Mease PJ, Genovese MC, Erondu N, Nirula A, Yuan FJ, Viswanathan HN.

Arthritis Care Res (Hoboken). 2015 Dec;67(12):1750-6. doi: 10.1002/acr.22653.

44.

Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS(®) Physical Function.

Schalet BD, Revicki DA, Cook KF, Krishnan E, Fries JF, Cella D.

J Gen Intern Med. 2015 Oct;30(10):1517-23. doi: 10.1007/s11606-015-3360-0.

45.

Introduction to special section on patient engagement.

Schwartz CE, Revicki DA.

Qual Life Res. 2015 May;24(5):1029-31. doi: 10.1007/s11136-015-0960-4. No abstract available.

PMID:
25786887
46.

Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2).

Matza LS, Murray LT, Phillips GA, Konechnik TJ, Dennehy EB, Bush EN, Revicki DA.

Patient. 2015 Oct;8(5):433-43. doi: 10.1007/s40271-014-0107-7.

47.

Introduction to special section: quantitative methods.

Revicki DA, Schwartz CE.

Qual Life Res. 2015 Jan;24(1):1-3. doi: 10.1007/s11136-014-0887-1. No abstract available.

PMID:
25519939
48.

The impact of medication on health-related quality of life in patients with generalized anxiety disorder.

Wilson H, Mannix S, Oko-osi H, Revicki DA.

CNS Drugs. 2015 Jan;29(1):29-40. doi: 10.1007/s40263-014-0217-8. Review.

PMID:
25516469
49.

US valuation of health outcomes measured using the PROMIS-29.

Craig BM, Reeve BB, Brown PM, Cella D, Hays RD, Lipscomb J, Simon Pickard A, Revicki DA.

Value Health. 2014 Dec;17(8):846-53. doi: 10.1016/j.jval.2014.09.005.

50.

Developing item banks for measuring pediatric generic health-related quality of life: an application of the International Classification of Functioning, Disability and Health for Children and Youth and item response theory.

Gandhi PK, Thompson LA, Tuli SY, Revicki DA, Shenkman E, Huang IC.

PLoS One. 2014 Sep 30;9(9):e107771. doi: 10.1371/journal.pone.0107771. eCollection 2014.

Supplemental Content

Loading ...
Support Center